Landmark Trials

230 practice-changing oncology trials.

• DESTINY-Breast05 — Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With High-Risk HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Therapy
• LIBRETTO-432 — Adjuvant Selpercatinib Versus Placebo in Resected Stage IB–IIIA RET Fusion–Positive Non–Small Cell Lung Cancer
• RAMPART — Renal Adjuvant MultiPle Arm Randomised Trial — Adjuvant Durvalumab Alone or Combined with Tremelimumab in Resected Primary Renal Cell Carcinoma at Intermediate or High Risk of Relapse
• PROTEUS — Neoadjuvant and Adjuvant Apalutamide plus Androgen Deprivation Therapy around Radical Prostatectomy in High-Risk Localized or Locally Advanced Prostate Cancer
• TALAPRO-3 — Talazoparib plus Enzalutamide in DDR/HRR Gene-Altered Metastatic Castration-Sensitive Prostate Cancer
• CAPItello-281 — Capivasertib plus Abiraterone and Prednisone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
• POTOMAC — Durvalumab plus BCG Induction and Maintenance in High-Risk BCG-Naive Non-Muscle Invasive Bladder Cancer
• MARIPOSA-2 — Amivantamab plus Chemotherapy (with or without Lazertinib) vs Chemotherapy in EGFR-Mutated NSCLC after Osimertinib
• PAPILLON — Amivantamab plus Carboplatin-Pemetrexed in First-Line EGFR Exon 20 Insertion-Mutated NSCLC
• CodeBreaK 200 — Sotorasib versus Docetaxel in Previously Treated KRAS G12C-Mutated NSCLC
• KRYSTAL-1 — Adagrasib in KRAS G12C-Mutated Advanced Solid Tumors including NSCLC
• HER2CLIMB — Tucatinib plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer
• CheckMate-8HW — Nivolumab plus Ipilimumab versus Chemotherapy in First-Line MSI-H/dMMR Metastatic Colorectal Cancer
• PACIFIC — A Global Study to Assess the Effects of Durvalumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable NSCLC
• HIMALAYA — Durvalumab With or Without Tremelimumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma
• POSEIDON — Durvalumab (± Tremelimumab) Plus Chemotherapy Versus Chemotherapy in First-Line Metastatic NSCLC
• ADAURA — Osimertinib Versus Placebo in Patients With Stage IB-IIIA EGFR-Mutated NSCLC After Complete Tumour Resection
• KEYNOTE-189 — Pemetrexed and Platinum Chemotherapy With or Without Pembrolizumab in Metastatic Nonsquamous NSCLC
• KEYNOTE-024 — Pembrolizumab Versus Platinum-Based Chemotherapy in Metastatic NSCLC With PD-L1 >=50%
• CheckMate 227 — Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment in Stage IV or Recurrent NSCLC
• FLAURA — Osimertinib Versus Standard EGFR-TKI in First-Line EGFR-Mutated Advanced NSCLC
• CROWN — Lorlatinib Versus Crizotinib in First-Line Treatment of Advanced ALK-Positive NSCLC
• ALEX — Alectinib Versus Crizotinib in Treatment-Naive ALK-Positive Advanced NSCLC
• LAURA — Osimertinib Following Chemoradiation in Stage III Unresectable EGFR-Mutated NSCLC
• CheckMate 816 — Neoadjuvant Nivolumab Plus Chemotherapy Versus Chemotherapy in Resectable NSCLC
• KEYNOTE-522 — Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy for Early Triple-Negative Breast Cancer
• KEYNOTE-A18 — Pembrolizumab plus Chemoradiotherapy vs Placebo plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
• DESTINY-Breast04 — Trastuzumab Deruxtecan vs Physician's Choice Chemotherapy in HER2-Low Metastatic Breast Cancer
• DESTINY-Breast03 — Trastuzumab Deruxtecan vs Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
• CLEOPATRA — Clinical Evaluation of Pertuzumab and Trastuzumab: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
• APHINITY — Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer
• monarchE — Abemaciclib plus Endocrine Therapy as Adjuvant Treatment for High-Risk HR-Positive, HER2-Negative Early Breast Cancer
• SOFT — Suppression of Ovarian Function Trial: Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
• OlympiA — Adjuvant Olaparib in Patients with Germline BRCA-Mutated High-Risk HER2-Negative Early Breast Cancer
• TAILORx — Trial Assigning Individualized Options for Treatment (Rx)
• KATHERINE — Trastuzumab Emtansine vs Trastuzumab as Adjuvant Therapy for Residual Invasive HER2-Positive Breast Cancer After Neoadjuvant Therapy
• KEYNOTE-177 — Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
• MOSAIC — Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
• CheckMate 649 — Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Previously Untreated Advanced Gastric, GEJ, and Esophageal Adenocarcinoma
• NAPOLI-3 — NALIRIFOX Versus Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
• FLOT4 — Perioperative FLOT Versus ECF/ECX in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
• PRODIGE 4/ACCORD 11 — FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer
• PRODIGE 24 — Modified FOLFIRINOX Versus Gemcitabine as Adjuvant Therapy for Resected Pancreatic Cancer
• IMbrave150 — Atezolizumab Plus Bevacizumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma
• TOPAZ-1 — Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
• CheckMate 577 — Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
• CROSS — Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study
• CheckMate 067 — Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma
• KEYNOTE-006 — Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab Compared to Ipilimumab in Participants With Advanced Melanoma
• S1801 — A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
• COMBI-d — A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-Mutant Melanoma
• CheckMate 214 — Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
• KEYNOTE-426 — Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Axitinib Versus Sunitinib Monotherapy as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma
• CLEAR — Lenvatinib Plus Everolimus or Lenvatinib Plus Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
• EV-302 — Enfortumab Vedotin Plus Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
• JAVELIN Bladder 100 — Avelumab First-Line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone in Advanced Urothelial Carcinoma
• CheckMate 274 — An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Participants With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
• VISION — Study of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
• ZUMA-1 — A Phase 1-2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects With Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
• JULIET — Study of Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• POLARIX — A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
• ECHELON-1 — A Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
• RATIFY — Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (RATIFY)
• MAIA — Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
• ALCYONE — A Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
• CLL14 — A Study of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia and Coexisting Medical Conditions
• MURANO — A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
• GALLIUM — A Study of Obinutuzumab Plus Chemotherapy Compared With Rituximab Plus Chemotherapy in Participants With Previously Untreated Follicular Lymphoma
• SOLO-1 — Olaparib Maintenance Monotherapy in Patients With BRCA-Mutated Advanced Ovarian Cancer Following First-Line Platinum-Based Chemotherapy
• PAOLA-1 — Platine, Avastin and OLAparib in 1st Line (PAOLA-1/ENGOT-ov25)
• GOG-0218 — A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Advanced Ovarian Cancer
• NRG-GY018 — Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
• PORTEC-3 — Randomized Trial of Radiation Therapy With or Without Chemotherapy for High-Risk Endometrial Cancer (PORTEC-3)
• KEYNOTE-048 — A Study of Pembrolizumab for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
• RTOG-0129 — Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer (RTOG 0129)
• Stupp Trial — Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (EORTC 26981/22981-NCIC CE.3)
• STAMPEDE — Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) - Abiraterone Comparison
• KEYNOTE-001 — Phase 1 Study of Pembrolizumab (MK-3475) in Patients With Advanced Melanoma and Non-Small Cell Lung Cancer
• KEYNOTE-158 — Phase 2 Basket Study of Pembrolizumab in Patients With Advanced Solid Tumors (MSI-H/dMMR and TMB-High Cohorts)
• KEYNOTE-042 — Pembrolizumab Versus Platinum-Based Chemotherapy in PD-L1-Positive Advanced NSCLC
• KEYNOTE-407 — Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC
• KEYNOTE-671 — Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy in Resectable NSCLC
• KEYNOTE-045 — Pembrolizumab Versus Chemotherapy for Advanced Urothelial Carcinoma After Platinum Therapy
• KEYNOTE-355 — Pembrolizumab Plus Chemotherapy Versus Chemotherapy for Metastatic Triple-Negative Breast Cancer
• KEYNOTE-590 — Pembrolizumab Plus Chemotherapy for Advanced Esophageal and Gastroesophageal Junction Cancer
• KEYNOTE-826 — Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
• KEYNOTE-564 — Adjuvant Pembrolizumab Versus Placebo in Renal Cell Carcinoma After Nephrectomy
• CheckMate 9LA — Nivolumab Plus Ipilimumab With Two Cycles of Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Metastatic NSCLC
• CheckMate 743 — Nivolumab Plus Ipilimumab Versus Chemotherapy for First-Line Unresectable Malignant Pleural Mesothelioma
• CheckMate 025 — Nivolumab Versus Everolimus in Previously Treated Advanced Renal Cell Carcinoma
• CheckMate 238 — Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma
• CheckMate 017 & 057 — Nivolumab Versus Docetaxel in Previously Treated Advanced Squamous (017) and Nonsquamous (057) Non-Small Cell Lung Cancer
• E1684 — High-Dose Interferon Alfa-2b Adjuvant Therapy Versus Observation in Resected High-Risk Melanoma
• E4599 — Carboplatin and Paclitaxel With or Without Bevacizumab in Advanced Non-Squamous NSCLC
• E1199 — Adjuvant Paclitaxel and Docetaxel, Weekly Versus Every-3-Weeks, After Doxorubicin-Cyclophosphamide in Node-Positive/High-Risk Breast Cancer
• NSABP B-06 — Total Mastectomy Versus Lumpectomy With or Without Radiation for Early Invasive Breast Cancer
• NSABP B-31 / N9831 — Adjuvant Trastuzumab Added to Doxorubicin-Cyclophosphamide Followed by Paclitaxel in HER2-Positive Breast Cancer
• CALGB 9741 — Dose-Dense Versus Conventionally Scheduled Adjuvant Chemotherapy for Node-Positive Breast Cancer
• CALGB 9343 — Lumpectomy Plus Tamoxifen With or Without Radiation in Older Women With Early Estrogen-Receptor-Positive Breast Cancer
• CALGB/SWOG 80405 — Chemotherapy Plus Cetuximab or Bevacizumab as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer
• CALGB 100104 — Lenalidomide Maintenance Versus Placebo After Autologous Stem-Cell Transplantation in Multiple Myeloma
• KEYNOTE-811 — Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
• CheckMate 141 — Nivolumab Versus Investigator's Choice in Recurrent or Metastatic Platinum-Refractory Head and Neck Squamous Cell Carcinoma
• CHAARTED — Chemohormonal Therapy Versus Androgen Ablation Alone for Metastatic Hormone-Sensitive Prostate Cancer
• E2100 — Paclitaxel With or Without Bevacizumab as First-Line Therapy for Metastatic Breast Cancer
• E1912 — Ibrutinib-Rituximab Versus Chemoimmunotherapy (FCR) in Younger Patients With Untreated CLL
• NSABP B-04 — Radical Mastectomy Versus Less Extensive Surgery With or Without Radiation for Operable Breast Cancer
• NSABP B-18 — Preoperative Versus Postoperative Doxorubicin-Cyclophosphamide Chemotherapy for Operable Breast Cancer
• NSABP B-32 — Sentinel-Lymph-Node Resection Versus Conventional Axillary Dissection in Node-Negative Breast Cancer
• NSABP P-1 — Tamoxifen for the Prevention of Breast Cancer in High-Risk Women (Breast Cancer Prevention Trial)
• RTOG 9111 — Concurrent Chemoradiotherapy Versus Induction Chemotherapy or Radiation Alone for Larynx Preservation
• RTOG 9802 — Radiation Therapy With or Without PCV Chemotherapy for High-Risk Low-Grade Glioma
• RTOG 0617 — Standard-Dose Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Stage III NSCLC
• RTOG 9402 — Radiation With or Without PCV Chemotherapy for Anaplastic Oligodendroglial Tumors
• ACOSOG Z0011 — Axillary Dissection Versus No Axillary Dissection in Women With Sentinel-Node Metastasis
• MSLT-II — Completion Lymph-Node Dissection Versus Observation for Sentinel-Node Metastasis in Melanoma
• Dutch TME Trial — Preoperative Short-Course Radiotherapy Plus Total Mesorectal Excision for Rectal Cancer
• CLL8 — Fludarabine-Cyclophosphamide With or Without Rituximab in Previously Untreated CLL
• FIRE-3 — FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First-Line KRAS Wild-Type Metastatic Colorectal Cancer
• HD15 — Escalated-Dose BEACOPP Regimens and PET-Guided Radiotherapy for Advanced Hodgkin Lymphoma
• GeparSepto — Nab-Paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer
• AMAROS — Axillary Radiotherapy Versus Axillary Dissection for Sentinel-Node-Positive Breast Cancer
• ACTS-GC — Adjuvant S-1 Chemotherapy After D2 Gastrectomy for Stage II/III Gastric Cancer
• CLASSIC — Adjuvant Capecitabine and Oxaliplatin (CAPOX) After D2 Gastrectomy for Gastric Cancer
• JCOG9501 — D2 Versus D2 Plus Para-Aortic Nodal Dissection Gastrectomy for Gastric Cancer
• IPASS — Gefitinib Versus Carboplatin-Paclitaxel as First-Line Therapy in Selected Asian NSCLC Patients
• ATTRACTION-2 — Nivolumab Versus Placebo in Heavily Pretreated Advanced Gastric Cancer (Asian)
• DESTINY-Breast09 — Trastuzumab Deruxtecan With or Without Pertuzumab vs Taxane, Trastuzumab, and Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer
• MARIPOSA — Amivantamab plus Lazertinib vs Osimertinib in First-Line EGFR-Mutated Advanced NSCLC
• NADINA — Neoadjuvant Nivolumab plus Ipilimumab vs Adjuvant Nivolumab in Resectable Stage III Melanoma
• DeLLphi-304 — Tarlatamab vs Chemotherapy in Second-Line Small-Cell Lung Cancer
• EMERALD-3 — STRIDE (Durvalumab plus Tremelimumab) With or Without Lenvatinib Combined With Transarterial Chemoembolization (TACE) in Embolization-Eligible Hepatocellular Carcinoma
• FIGHT-302 — Pemigatinib Versus Gemcitabine Plus Cisplatin as First-Line Therapy for Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
• MATTERHORN — Perioperative Durvalumab plus FLOT in Resectable Gastric and Gastroesophageal Junction Cancer
• EMBER-3 — Imlunestrant With or Without Abemaciclib vs Standard Endocrine Therapy in ER-Positive Advanced Breast Cancer
• EMBARK — Enzalutamide With or Without Leuprolide in High-Risk Biochemically Recurrent Nonmetastatic Hormone-Sensitive Prostate Cancer
• NATALEE — Ribociclib plus Endocrine Therapy as Adjuvant Treatment in HR-Positive/HER2-Negative Early Breast Cancer
• GOG-111 — Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
• GOG-120 — Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
• GOG-122 — Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
• GOG-172 — Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
• GOG-204 — Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma
• GOG-209 — Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
• GOG-240 — Improved Survival with Bevacizumab in Advanced Cervical Cancer
• GOG-258 — Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
• RTOG 9408 — Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
• RTOG 9601 — Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
• RTOG 0529 — RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal
• ECOG 1594 — Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer
• ECOG 1496 — Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
• ECOG 3200 — Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
• ECOG 2805 — Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
• NCI-MATCH — Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131)
• NSABP B-14 — A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients With Node-Negative Breast Cancer Who Have Estrogen-Receptor-Positive Tumors
• NSABP B-17 — Lumpectomy Compared With Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer (DCIS)
• NSABP C-04 — Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From NSABP C-04
• NSABP STAR — Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes
• NSABP C-07 — Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
• SWOG-8710 — Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
• PCPT — The Prostate Cancer Prevention Trial: The Influence of Finasteride on the Development of Prostate Cancer
• SELECT — Selenium and Vitamin E Cancer Prevention Trial (SELECT): Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers
• SWOG-S8814 — Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen-Receptor-Positive Breast Cancer on Chemotherapy
• POEMS — POEMS/S0230: Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
• SWOG-S1826 — S1826: A Phase 3 Randomized Study of Nivolumab plus AVD versus Brentuximab Vedotin plus AVD in Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma
• CALGB 8541 — Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
• CALGB 8811 — A Five-Drug Remission Induction Regimen with Intensive Consolidation for Adults with Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811
• CALGB 140503 — Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
• NSABP B-20 — National Surgical Adjuvant Breast and Bowel Project Protocol B-20
• NSABP C-03 — National Surgical Adjuvant Breast and Bowel Project Protocol C-03
• EORTC 18071 — European Organisation for Research and Treatment of Cancer 18071
• MINDACT — Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy
• SWOG S0777 — SWOG S0777
• AALL0331 — Standard-Risk B-Precursor Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase III Study of Risk-Directed Therapy (Children's Oncology Group AALL0331)
• AAML1331 — A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid (Children's Oncology Group AAML1331)
• AALL1731 — A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (Children's Oncology Group AALL1731)
• AALL1331 — Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia
• JCOG 9907 — A Randomized Controlled Trial of Chemotherapy With 5-FU and Cisplatin Before and After Surgery for Stage II/III Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
• RxPONDER — A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
• MONALEESA-2 — Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (MONALEESA-2)
• MONARCH 3 — A Study of Abemaciclib (LY2835219) in Combination With a Nonsteroidal Aromatase Inhibitor in Postmenopausal Women With Breast Cancer (MONARCH 3)
• PALOMA-2 — Palbociclib (PD-0332991) Combined With Letrozole Versus Letrozole for First-Line Treatment of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
• ASCENT — Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)
• TROPiCS-02 — Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in HR+/HER2- Metastatic Breast Cancer (TROPiCS-02)
• FLAURA2 — Osimertinib With or Without Chemotherapy as First-Line Treatment in EGFR-Mutated Advanced NSCLC (FLAURA2)
• CASPIAN — Durvalumab ± Tremelimumab With Platinum-Etoposide in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
• IMpower133 — Atezolizumab With Carboplatin and Etoposide in Extensive-Stage Small Cell Lung Cancer (IMpower133)
• RASolute 302 — Daraxonrasib (RMC-6236) Versus Investigator's Choice of Chemotherapy in Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (RASolute 302)
• BEACON CRC — Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer (BEACON CRC)
• KEYNOTE-859 — Pembrolizumab Plus Chemotherapy Versus Chemotherapy in HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-859)
• SPOTLIGHT — Zolbetuximab Plus mFOLFOX6 in Claudin-18.2-Positive, HER2-Negative Advanced Gastric or GEJ Adenocarcinoma (SPOTLIGHT)
• GLOW — Zolbetuximab Plus CAPOX in Claudin-18.2-Positive, HER2-Negative Advanced Gastric or GEJ Adenocarcinoma (GLOW)
• ESOPEC — Perioperative FLOT Versus Neoadjuvant CROSS Chemoradiation in Resectable Esophageal Adenocarcinoma (ESOPEC)
• CheckMate 9ER — Nivolumab Plus Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma (CheckMate 9ER)
• LATITUDE — Abiraterone Acetate Plus Prednisone Added to Androgen Deprivation Therapy in High-Risk Metastatic Hormone-Sensitive Prostate Cancer (LATITUDE)
• TITAN — Apalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer (TITAN)
• ARCHES — Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer (ARCHES)
• PROfound — Olaparib in Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations (PROfound)
• RUBY — Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer (RUBY)
• DUO-E — Durvalumab Plus Carboplatin-Paclitaxel With or Without Olaparib in Advanced or Recurrent Endometrial Cancer (DUO-E)
• TRANSCEND — Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma (TRANSCEND NHL 001)
• ZUMA-7 — Axicabtagene Ciloleucel Versus Standard Care as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)
• TRANSFORM — Lisocabtagene Maraleucel Versus Standard Care as Second-Line Therapy for Large B-Cell Lymphoma (TRANSFORM)
• MajesTEC-1 — Teclistamab in Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
• CARTITUDE-4 — Ciltacabtagene Autoleucel Versus Standard Care in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
• KarMMa-3 — Idecabtagene Vicleucel Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (KarMMa-3)
• AGILE — Ivosidenib Plus Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia (AGILE)
• GLOW — Fixed-Duration Ibrutinib Plus Venetoclax in Older or Comorbid Patients With Untreated Chronic Lymphocytic Leukemia (GLOW)
• RELATIVITY-047 — Nivolumab Plus Relatlimab Versus Nivolumab in Untreated Advanced Melanoma (RELATIVITY-047)
• CARAVAGGIO — Apixaban Versus Dalteparin for Cancer-Associated Venous Thromboembolism (CARAVAGGIO)
• SELECT-D — Rivaroxaban Versus Dalteparin for Cancer-Associated Venous Thromboembolism (SELECT-D)
• DESTINY-Breast06 — Trastuzumab Deruxtecan Versus Physician's Choice Chemotherapy in HR-Positive, HER2-Low or HER2-Ultralow Metastatic Breast Cancer After Endocrine Therapy
• NIAGARA — Perioperative Durvalumab With Neoadjuvant Chemotherapy in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
• BREAKWATER — Encorafenib Plus Cetuximab With Chemotherapy in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer
• NETTER-1 — 177Lu-DOTATATE Plus Octreotide LAR Versus High-Dose Octreotide LAR in Advanced Midgut Neuroendocrine Tumors
• PALETTE — Pazopanib Versus Placebo in Metastatic Non-Adipocytic Soft-Tissue Sarcoma After Chemotherapy
• NETTER-2 — First-Line [177Lu]Lu-DOTA-TATE Plus Octreotide LAR in Advanced Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors
• INDIGO — Vorasidenib Versus Placebo in Residual or Recurrent Grade 2 IDH-Mutant Glioma After Surgery
• SOLAR-1 — Alpelisib Plus Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer (SOLAR-1)
• MONALEESA-3 — Ribociclib Plus Fulvestrant in Postmenopausal HR+/HER2- Advanced Breast Cancer (MONALEESA-3)
• MONALEESA-7 — Ribociclib Plus Endocrine Therapy in Premenopausal HR+/HER2- Advanced Breast Cancer (MONALEESA-7)
• IMpower110 — Atezolizumab Versus Chemotherapy in Untreated PD-L1-Selected Advanced NSCLC (IMpower110)
• CARTITUDE-1 — Ciltacabtagene Autoleucel (Cilta-cel), a BCMA CAR-T Therapy, in Relapsed/Refractory Multiple Myeloma (CARTITUDE-1)
• LEAP-002 — Pembrolizumab Plus Lenvatinib Versus Lenvatinib in First-Line Advanced Hepatocellular Carcinoma (LEAP-002)
• DESTINY-Gastric01 — Trastuzumab Deruxtecan (T-DXd) Versus Chemotherapy in HER2-Positive Advanced Gastric or GEJ Adenocarcinoma (DESTINY-Gastric01)
• POLLUX — Daratumumab Plus Lenalidomide-Dexamethasone Versus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma (POLLUX)
• CASSIOPEIA — Daratumumab Plus Bortezomib-Thalidomide-Dexamethasone (D-VTd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (CASSIOPEIA)
• DREAMM-2 — Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (DREAMM-2)
• MONARCH 2 — Abemaciclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Progressing on Endocrine Therapy (MONARCH 2)
• PALOMA-3 — Palbociclib Plus Fulvestrant in HR+/HER2- Metastatic Breast Cancer Progressing on Endocrine Therapy (PALOMA-3)
• COLUMBUS — Encorafenib Plus Binimetinib Versus Vemurafenib in BRAF V600-Mutant Advanced Melanoma (COLUMBUS)